Ontario's leading advocate for the life sciences sector
Read this article, published in the Toronto Star, about Montreal-based start-up Jenthera Therapeutics who are developing in vivo gene editing that can directly modify a person’s DNA and fine tune immune cells to find and attack specific types of cancer.
Jenthera presented at the OBIO® Investment Summit.
This Entrepreneurship Week, University of Toronto Entrepreneurship is highlighting U of T-affiliated start-ups to keep an eye on in 2024.
HDAX Therapeutics, co-founded by alumnae Pimyupa Manaswiyoungkul and Nabanita Nawar, is looking to tackle the problem with a preventative drug that has delivered promising results in pre-clinical studies.
HDAX Therapeutics is an OBIO® member, an alumnus of the BDSP™ and WiHI Seed programs and presented at the OBIO® Investment Summit.
Read this article, published in The Logic, profiling Vena Medical’s journey of making a breakthrough innovation that sends cameras into human brains. The physicians at The Ottawa Hospital (TOH) were the first in the world to use new stroke technology, the Vena MicroAngioscope™, in a patient procedure. Equipped with the world’s smallest camera, the device goes inside veins and arteries, allowing physicians to see inside the blood vessels of the patient’s brain.
Vena Medical is an OBIO® member, an alumnus of our BDSP™, CAAP®, EAHN™ and H2BB™ programs and presented at the OBIO® Investment Summit.
MIMOSA Diagnostics, a medical equipment manufacturing company who is making a medical device for non-invasively assessing tissue damage, has received Health Canada approval six months after it launched its technology in the U.S. The sign-off paves the way for the company to sell its MIMOSA Pro device north of the border, following comments last year by CEO Dr. Karen Cross that pursuing American approval first would ease the Canadian compliance process because the two systems have similar requirements.
MIMOSA is an OBIO® member, an alumnus of our BDSP™, H2BB™ and HealthMINT™ programs and presented at the OBIO® Investment Summit.
Mediphage Bioceuticals, a biotechnology company driving the next generation of genetic medicines, recently announced closing of its Seed financing round. A mix of early Mediphage supporters, including CCRM Enterprises Holdings Ltd, Riverine Ventures, and Bio Med Ventures, as well as new investors participated in the syndicate. The investment will drive the company’s internal therapeutic and manufacturing programs, while enabling Mediphage to continue supporting its growing number of external collaborations with pharmaceutical and biotechnology companies, CDMOs, and national research organizations.
Mediphage is an OBIO® member, an alumnus of our BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs and presented at the OBIO® Investment Summit.
KA Imaging’s Team Lead for Spectral Imaging, Steven Tilley, will be presenting at the upcoming European Congress of Radiology (ECR). The study titled “Dual-Energy Tomosynthesis of the Chest using a Triple Layer X-ray Detector”, which yielded promising results, will be part of a Research Presentation Session.
KA Imaging will also be part of the technical exhibition, showcasing the Reveal 35C detector (CE Marked), as well as mobile solutions. The company can be found at Expo X2 (Lower Level), booth #226. The Congress will be held in Vienna from February 28 to March 3.
KA Imaging is an OBIO® member, an alumnus of our BDSP™, CAAP®, EAHN™, H2BB™, HealthMINT™ and presented at the OBIO® Investment Summit.
Eurofins CDMO Alphora Inc., a contract drug and manufacturing organization based in Mississauga, recently announced the successful completion of its state-of-the-art 3,300 square feet pilot-scale Biologics development facility in Mississauga. Specializing in monoclonal antibodies (mAbs) and mammalian-based therapeutic proteins, the facility offers comprehensive services in upstream processing, downstream development, process design, GMP QC testing, with up to 200 L scale for Pre-Clinical and Phase I Supply. Additionally, the facility supports fully integrated conjugation services for antibody drug conjugate (ADC) candidate development, leveraging its extensive experience in active pharmaceutical ingredients (API) and highly potent active pharmaceutical ingredients (HPAPI).
We are pleased to count Eurofins CDMO Alphora as an OBIO® member, and also as a sponsor of the 2024 OBIO® Investment Summit.
Toronto, ON – February 21, 2024 – The OBIO® Investment Summit brings together global investors with emerging Canadian life sciences and health tech companies, technology innovators and ecosystem partners. This year, the Summit was held from February 14-16 at our new home, the Schwartz Reisman Innovation Centre in downtown Toronto. The Summit showcased over 90 of Canada's most promising early-stage companies, top universities and research institutions, giving them the opportunity to convene with international investors, multinational pharmaceutical companies and medtech corporations.
In the words of Dr. Maura Campbell, President and CEO of OBIO®, “The Summit enables Pre-Seed, Seed and Series A life science companies to share their innovative technologies with international investors, highlighting the strength of our industry and investment opportunities across Canada. We are proud of our efforts to support companies in securing investment to develop and commercialize their leading-edge technologies domestically, and we will continue to amplify the success of the Canadian ecosystem through our Summit."
The OBIO® Investment Summit is a catalyst that keeps attracting investors and investment to Ontario and to Canada. Companies that have presented at the Summit have raised over CAD $1.6 billion since 2018. Dr. Campbell continued, "Every year, we build on our past success. The 2024 Summit featured an expanded Business Development Forum, connecting international medtech and pharmaceutical companies with early-stage Canadian companies to explore research collaborations and licensing opportunities for their technologies."
OBIO® is supported by a Government of Canada investment of $10 million, through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), to help scale up healthcare innovation and create inclusive economic growth in southern Ontario. To date this investment has led to the creation/maintenance of 270 jobs, 159 new intellectual properties have been created or licensed, and over 625 people have received training or mentorship.
“The OBIO® Investment Summit is an important networking opportunity for our healthcare institutions, investors and health science companies to connect and share ideas,” said the Honourable Filomena Tassi, Minister responsible for the Federal Economic Development Agency for Southern Ontario. “Supporting organizations, like OBIO®, that encourage the participation of women in leadership roles in the health sector is critical for the long-term success of our healthcare system. This work is instrumental in ensuring better health care for Canadians now, and into the future.”
The Government of Ontario is also supporting OBIO® with up to $9.7 million to help Ontario companies in the life sciences sector to adopt, develop and bring to market critical technologies, such as 5G and advanced networks, ethical artificial intelligence, blockchain, cybersecurity, quantum and robotics.
“Ontario is home to the largest life sciences sector in Canada, with 1,900 firms employing over 70,000 highly-skilled professionals,” said the Honourable Victor Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade. “Through the Investment Summit, OBIO® is driving innovation in our life sciences ecosystem and supporting innovators as they develop and commercialize their cutting-edge technologies.”
"The early-stage life sciences companies at the 2024 OBIO® Investment Summit highlighted the vibrant nature and talent present in the Canadian community. With representation across the broader Bayer Radiology and Pharmaceuticals business, the Bayer team was able to connect with current partners, identify new opportunities and also network with a number of public entities,” said Jerry Orban, Country Head, Bayer Radiology Canada. “We could feel the collaboration emanating from the walls of the Schwartz Reisman Innovation Centre. The forum was exceptional with many companies aligned with our strategic offerings and several that brought what we consider to be industry-changing technology. What we have in the Canadian life sciences market is a true gem built on incredible talent, science, public funding and private partnerships, and Bayer is proud to be part of that ecosystem. We look forward to attending again in 2025. Thank you to the entire OBIO® team.”
“OBIO® is an important advocate for the Ontario healthcare technology sector and has been a true friend to AmacaThera since our spinout from the University of Toronto in 2016,” said Mike Foorer, VP Business Development & General Manager, AmacaThera. “AmacaThera has been fortunate to present at the Summit during our initial growth phase and are thrilled to see the next wave of startups doing the same.”
OBIO® will continue to collaborate with its partners, including incubators and accelerators, to foster investment in Canada. The life sciences sector and the OBIO® Investment Summit can only succeed with the backing of a robust, supportive ecosystem with a shared vision of the future.
About OBIO®
Founded in 2009, OBIO® is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies positioning Canada as a leader in the international marketplace. OBIO® advances this goal through collaborative partnerships with industry, the investment community, academia, the health system and government.
For more information, please visit www.obio.ca and follow OBIO® on LinkedIn and X (formerly Twitter).
About FedDev Ontario
For 14 years, the Government of Canada, through FedDev Ontario, has worked to advance and diversify the southern Ontario economy through funding opportunities and business services that support innovation, growth and job creation in Canada’s most populous region. The Agency has delivered impressive results, which can be seen in southern Ontario businesses that are creating innovative technologies, improving productivity, growing revenues, creating jobs, and in the economic advancement of communities across the region. Learn more about the impacts the Agency is having in southern Ontario by exploring our pivotal projects, our Southern Ontario Spotlight, and FedDev Ontario’s Twitter, Facebook, Instagram and LinkedIn.
Media contacts:
Edward Hutchinson
Press Secretary
Office of the Minister responsible for the Federal Economic Development Agency for Southern Ontario
edward.hutchinson@feddevontario.gc.ca
Doriane Rey
Manager, Marketing & Events
OBIO®
dorianerey@obio.ca
January 31, 2024 (Vancouver, B.C.) – Over 350,000 patients in Canada are admitted into the intensive care unit (ICU) annually, with 40% of those patients needing invasive mechanical ventilation. Managing mechanically ventilated patients can be complex due to providers having to simultaneously treat the underlying condition and the potential impacts a ventilator may have on the patient, which can lead to costly complications. The most common ventilator related complications or injuries are to a patient’s heart or lungs. In fact, up to 50% of mechanically ventilated patients experience complications, contributing in part to the ICU’s usage of 20 percent of hospital resources.
Currently, there is no real time, single solution to evaluate the impact on a patient’s cardio-pulmonary health from mechanical ventilation. Current methods are often invasive and time consuming, require extensive training and only provide partial information by focusing on one organ and ignoring the impacts of any intervention on the other.
Through OBIO’s Early Adopter Health Network (EAHN™), Rostrum Medical Innovations, a British Columbia-based medical device start-up, secured a partnership with Southlake Regional Health Centre to evaluate Pulmonary Blood Flow (PBF) when measured by their novel VQm® System as compared to the reference standard in the ICU.
Rostrum Medical Innovation’s VQm® System is a bedside cardio-pulmonary health monitoring system that addresses the gap in clinical monitoring solutions of the heart and lungs for invasively mechanically ventilated patients in the ICU. The VQm® System consists of a standalone monitor, a proprietary sensor and a per patient that connects the monitor to any standard ventilator breathing circuit. Rostrum’s VQm® System also measures dead space, shunt fraction and functional residual capacity, giving providers the information they need to streamline ICU clinical workflows and reduce costs for mechanically ventilated patients.
This evaluation which is the product’s first clinical application in an ICU setting has demonstrated VQm® System’s ability to detect changes in PBF. Compared to the reference standard, the VQm® System showed a concordance of 83% to the standard of care. The VQm® System can also assess the impact of intravenous (IV) fluid on a patient’s heart and lung function allowing point of care adjustments which may reduce the rate of complications. Current ICU methods to generate the same type of data would cost upwards of $43,000 per patient per day, whereas the VQm® System can provide it daily for approximately $250 per patient for the duration of ICU care. Ultimately this solution has the potential to empower the healthcare team by giving them non-invasive, bedside access to valuable clinical measurements.
“We are very grateful to have worked with an amazing team from Southlake and we are proud with what the results are showing,” said Nathan Ayoubi, COO, Rostrum Medical Innovation. “We are committed to continuing our efforts to bring the VQm® System into other sites across the country.”
“The ability of this technology to generate physiological measurements non-invasively and in a semi-continuous manner could prove highly valuable within the ICU setting,” said Dr. Bryn Fell, Critical Care Medicine and Internal Medicine Specialist, Southlake Regional Health Centre. “We need to study this device in the ICU to see if any single or a combination of its four outputs could be used to tailor patient care, whether that be through more effective oxygenation and ventilation titration, fluid and pressor optimization, or another outcome. More study is needed, but preliminary results are promising.”
“We are pleased to provide an opportunity to a B.C.-based company to access the Ontario healthcare market and in turn potentially improve cost efficiencies in our healthcare system,” said Dr. Maura Campbell, President and CEO, OBIO®. “The success of this project truly exemplifies the pan-Canadian nature of EAHN™, which has partnered with companies and healthcare organizations in five provinces.”
About OBIO®
OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through their Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace. For more information, please visit OBIO.ca.
About Rostrum Medical Innovations
Rostrum Medical Innovations is dedicated to empowering medical practitioners with new and useful solutions to help solve everyday challenges that medical professionals face. Rostrum was established with a goal to deliver novel solutions to problematic uncertainties in modern day practice. With a team of some of the world’s most progressive clinicians, combined with engineering and business expertise with a history of commercial success, Rostrum is driven by one mission – to address clinical needs in healthcare. For more information, please visit www.rostrummedical.com.
About Southlake Regional Health Centre
Southlake is building healthy communities through outstanding care, innovative partnerships, and amazing people. We deliver a wide range of healthcare services to the communities of northern York Region and southern Simcoe County. Our advanced regional programs include Cancer Care and Cardiac Care and serve a broader population across the northern GTA and into Simcoe-Muskoka.
Our team of 6,000 staff, physicians, volunteers, students and Patient and Family Advisors are committed to creating an environment where the best experiences happen. As a recognition of our commitment to quality and patient safety, we have received the highest distinction of Exemplary Standing from Accreditation Canada.
With an annual operating budget of over $550 million, we are for one of Ontario’s most rapidly growing and aging populations and have developed an exciting plan for new facilities to serve our communities into the future. A member of the Southlake Community Ontario Health Team, we are working with our partners to deliver connected care to northern York Region and southern Simcoe County. For more information, please visit southlake.ca.
Media Contacts:
For more information, please contact:
Bibaswan Ghoshal
Senior Director, Technology Adoption
Ontario Bioscience Innovation Organization (OBIO®)
Nathan Ayoubi
Chief Operating Officer
Rostrum Medical Innovation
Lindsey Furlanic
Communications Strategist, Corporate Communications
Southlake Regional Health Centre
The physicians at The Ottawa Hospital (TOH) were the first in the world to use new stroke technology, the Vena MicroAngioscope™, in a patient procedure. Equipped with the world’s smallest camera, the device goes inside veins and arteries, allowing physicians to see inside the blood vessels of the patient’s brain. The use of the MicroAngioscope™ marks a significant development in the field of neurovascular care and will pave the way for new, innovative treatments for patients across the region.
Vena Medical is an OBIO® member, an alumnus of our BDSP™, CAAP®, EAHN™ and H2BB™ programs and presented at the OBIO® Investment Summit.
Virica Biotech Inc., a leading developer of cell enhancers for scaling of viral vectors and cell and gene therapies, is expanding bioprocessing services through a strategic partnership with Carleton University. Slated to open this spring, Virica’s new facility at the university multiplies the company’s capacity to provide high throughput virology services for customers looking to optimize production of their cell and gene therapies.
Virica Biotech is an OBIO® member, an alumnus of our BDSP™ program and recipient of the WiHI Leadership subsidy.
Swift Medical, a digital health technology company serving wound care providers, recently announced the successful closing of an $US8M round of financing co-led by current investors BDC Capital’s Women in Technology Venture Fund and funds managed by Virgo Investment Group. Swift utilizes artificial intelligence to improve clinical and economic outcomes in chronic and acute wound care, and this financing will accelerate its pace of technology enhancements.
Swift Medical is an OBIO® member and an alumnus of our BDSP™ and CAAP® programs.
Eurofins CDMO Alphora Inc., a contract drug and manufacturing organization based in Mississauga, recently announced the successful completion of its pilot-scale biologics development facility. Spanning 3,300 square feet, the facility is dedicated to the development and scaling of monoclonal antibodies (mAbs) and other mammalian-based therapeutic proteins.
We are pleased to count Eurofins CDMO Alphora as an OBIO® member, and also as a sponsor of the OBIO® Investment Summit happening this month.
Cohesys, an innovative medical device company focused on novel solutions for fracture treatment, has been selected for a $1.62M award by the Medical Technology Enterprise Consortium (MTEC) in collaboration with the Department of Defense (DoD) U.S. Army Medical Research and Development Command (USAMRDC). This award will advance development and clinical validation for BoneTape, a revolutionary resorbable bone fixation device designed to improve fracture treatment.
Cohesys is an OBIO® member and an alumnus of our BDSP™, CAAP® and H2BB™ programs.
K2 Medical Research, a leading clinical research organization committed to advancing medical science, has partnered with the renowned Magruder Eye Institute and Toronto-based medical AI company, RetiSpec, to redefine Alzheimer’s research through AI-driven technology. The partnership aims to leverage advanced artificial intelligence (AI) technology as a pre-screening tool for clinical trials, with the objective of enhancing trial accessibility and reducing the time associated with recruitment of eligible candidates. The collaboration aims to utilize RetiSpec’s AI technology as a pre-screening tool at Magruder Eye Institute.
Retispec is an OBIO® member, an alumnus of the BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs and presented at the OBIO® Investment Summit.
FluidAI Medical has developed an AI-powered monitor that detects post-operative gastrointestinal leaks, preventing complications that can arise from their late detection. The company’s investment will be used to research product improvements, build an automated assembly line to meet growing international demand and will create 38 jobs. In support of FluidAI’s investment, Ontario is providing over $1.4M in funding through the Advanced Manufacturing and Innovation Competitiveness stream of the Regional Development Program.
FluidAI Medical is an OBIO® member, an alumnus of BDSP™, CAAP®,EAHN™, H2BB™, HealthMINT™ and WiHI programs and presented at the OBIO® Investment Summit.
FluidAI Medical has developed an AI-powered monitor that detects post-operative gastrointestinal leaks, preventing complications that can arise from their late detection. The company’s investment will be used to research product improvements and build an automated assembly line to meet growing international demand and will create 38 jobs. In support of FluidAI’s investment, Ontario is providing over $1.4 million in funding through the Advanced Manufacturing and Innovation Competitiveness stream of the Regional Development Program.
KA Imaging is an OBIO® member, an alumnus of our BDSP™, CAAP®, EAHN™, H2BB™, HealthMINT™ and presented at the OBIO® Investment Summit.
January 4, 2024 (Toronto, ON) – The Ontario Bioscience Innovation Organization (OBIO®) is proud to announce significant milestones for its Women in Health Initiative (WiHI). Launched in July 2022 with support from the Government of Canada, through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), the OBIO® WiHI aims to bridge the gender disparity in the health science industry, particularly in senior management roles and leadership positions. The program offers comprehensive training, support and networking opportunities, empowering women with the skills and knowledge required to excel in leadership positions.
“Investing in the Women in Health Initiative (WiHI) is a crucial step in providing necessary supports and training so women can enter and flourish in the health and life sciences sector,” said the Honourable Filomena Tassi, Minister responsible for FedDev Ontario. “Southern Ontario is home to an abundance of healthcare-focused businesses—many more of which are women-led thanks to the committed efforts of WiHI. Our government is pleased to support the WiHI program as it works to increase the representation of women in this exciting field.”
In its first year, WiHI has made remarkable strides, supporting more than 325 women in the industry through experiential learning and financial support. This year, 11 women-led companies have been selected for the WiHI Seed Program, a key component of the initiative, which addresses the significant barriers that women-led companies face in accessing financing and support, especially in the health science sector where venture capital investment is at a historic low. The participating companies will benefit from this comprehensive six-month program and have access to expert networks, essential industry resources and skills, non-dilutive funding of up to $20,000 and potential equity investment.
“By providing a combination of early-stage capital and advisory support to women-led companies, the program addresses critical barriers faced by women entrepreneurs in the life science and health technology sectors,” said Dr. Maura Campbell, President & CEO of OBIO®. “The WiHI Seed Program is a critical step towards creating a more equitable, diverse and inclusive health science industry, empowering women entrepreneurs to thrive and be successful leaders.”
The selected companies for the WiHI Seed Program 2023 are A.I. VALI, Atorvia, Cove Neurosciences, HDAX Therapeutics, ImaginAble Solutions, mDETECT, MoxyPatch, Noa Therapeutics, Paradox Immunotherapeutics, Tenomix, and Vessl Prosthetics. These companies will receive comprehensive support, including non-dilutive funding, tailored advisory and coaching assistance, and opportunities to pitch for equity seed investment.
Other exciting WiHI highlights
We are delighted to welcome Monika Yazdanian (CEO and Co-founder of ToeFX Inc.) and Mai Elfarnawany (VP Engineering at Flosonics Medical) as recipients of the Women in Health Initiative Business Leadership Program, joining our previous eight awardees. The program celebrates women that are exemplary leaders, role models and mentors to other women in the industry. The awardees (who each receive a $50K wage subsidy) will participate in OBIO’s networking events and contribute as mentor leaders to a women’s professional development community to support workforce development in a sector where women are underrepresented.
“As a recipient of the WiHI Seed and Women in Health Initiative Business Leadership programs, I am deeply grateful for the opportunities and support OBIO® has provided to us. It is encouraging to see a focused effort to challenge systemic biases and create a level-playing field for women entrepreneurs,” said Natalie Galant, CEO of Paradox Immunotherapeutics. “The WiHI Seed Program symbolizes a transformative shift, empowering women entrepreneurs to excel and innovate. It's about creating a more inclusive future in health science, and I'm proud to be part of this change."
We are also excited to share that OBIO® WiHI has received the first ever honourable mention ACE (Advancement, Commitment, Engagement) award from the Healthcare Businesswomen’s Association (known as HBA), a global not-for-profit organization dedicated to furthering the advancement and impact of women in the business of healthcare. Represented in countries across the globe, the HBA serves a community of more than 75,000 individuals and 180 corporate partners.
The ACE award recognizes results-oriented initiatives fostered by organizations committed to ensuring that gender equity and leadership opportunities for women are part of their organizational DNA. A panel of healthcare leaders selects recipients for their excellence in advancing their female talent and removing the systemic barriers preventing timely progress to parity. Award criteria include measurable results, business performance, stewardship, execution, and sustainability. Read more.
Furthermore, WiHI was nominated for the Women Leaders in Pharma Awards for The Women Support Network award. This award recognizes companies that have supported the women’s network through networking, coaching, and mentoring.
About OBIO®
Founded in 2009, OBIO® is a not-for-profit membership-based innovation organization engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies that position Canada as a leader in the international marketplace. OBIO® advances this goal through collaborative partnerships with industry, the investment community, academia, the health care system and government. For more information, please visit obio.ca and follow OBIO® on LinkedIn and Twitter.
About FedDev Ontario
For 14 years, the Government of Canada, through FedDev Ontario, has worked to advance and diversify the southern Ontario economy through funding opportunities and business services that support innovation, growth and job creation in Canada’s most populous region. The Agency has delivered impressive results, which can be seen in southern Ontario businesses that are creating innovative technologies, improving productivity, growing revenues, creating jobs, and in the economic advancement of communities across the region. Learn more about the impacts the Agency is having in southern Ontario by exploring our pivotal projects, our Southern Ontario Spotlight, and FedDev Ontario’s Twitter, Facebook, Instagram and LinkedIn.
Media Contacts:
Doriane Rey
Manager, Marketing & Events
Ontario Bioscience Innovation Organization (OBIO®)
dorianerey@obio.ca
Edward Hutchinson
Press Secretary
Office of the Minister responsible for the Federal Economic Development Agency for Southern Ontario
edward.hutchinson@feddevontario.gc.ca
Xpan Inc., a medical device company focused on minimally invasive surgical innovation, secured FDA 510(k) clearance on the XpanTM Universal Trocar System – a device that can be tailored by surgeons during laparoscopic procedure, reducing complications and improving quality of care for patients.
XPAN is an OBIO® member, an alumnus of our BDSP™, CAAP®, H2BB™ and HealthMINT™ programs and presented at the OBIO® Investment Summit.
Realize Medical, an Ottawa-based virtual reality start-up, was featured on CTV News, showing how its virtual reality (VR) innovation, Elucis, enables surgeons to plan surgical procedures and improve patient treatment. Elucis lets you easily segment images into 3D models, collaborate with multiple remote colleagues and plan procedures all within virtual reality.
Realize Medical is a CAAP® company and presented at the 2021 OBIO® Investment Summit. They will be presenting at the 2024 OBIO® Investment Summit next month along with other exciting companies.
